← Back to headlines
Stifel Says Fulcrum Therapeutics Stock Drop 'Overdone'
Stifel analysts believe that the recent decline in Fulcrum Therapeutics' stock price is 'overdone,' suggesting an overreaction by the market.
25 Feb, 15:27 — 25 Feb, 15:27
ℹOnly 1 source covers this story
